Effect of simvastatin on bone markers in osteopenic women: Aplacebo-controlled, dose-ranging trial [ISRCTN85429598]

BMC Musculoskeletal Disorders

Volumn 3, Issue , 2002, Pages 1-5

  Hsia, Judith ^a   Morse, Megan ^a   Levin, Virginia ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; ETHNOLOGY; FEMALE; FRACTURE; HUMAN; LIPID BLOOD LEVEL; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; RANDOMIZED CONTROLLED TRIAL; ULTRASOUND;

EID: 34248399993     PISSN: 14712474     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-3-7     Document Type: Article

References (21)

1. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G: Stimulation of Bone Formation in Vitro and in Rodents by HMG coA reductase inhibitors. Science 1999, 286:1946-9
2. Russell RG, Robers MJ, Frith JC, et al: The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999, 14:53-65
3. Fisher JE, Halasy JM, Masarachia PJ, Wesolowiski G, Rodan GA, Reszka AA: Alendronate mechanism of action: inhibition of osteoclastogenesis and bone resorption are mimicked by lovastatin and blocked by geranygeraniol. Bone 1998, 23(Suppl):S399
4. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Harris F, Duong T, Cummings SR: HMG coA reductase inhibitor Use, Bone Mass and Fracture: An Analysis of Two Prospective Studies. J Bone Miner Res 1999, 14(suppl 1):S179
5. Chan KA, Andrade SE, Boles M, Buist DSM, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R: Inhibitors of hydroxymethylgutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000, 355:2185-8
6. Wang PS, Solomon DH, Mogun H, Avorn J: HMG-CoA Reductase Inhibitors and the Risk of Hip Fractures in Elderly Patients. JAMA 2000, 283:3211-6
7. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H: HMG-CoA Reductase Inhibitors and the Risk of Fractures. JAMA 2000, 283:3205-10
8. Van Staa T-P, Wegman S, de Vries F, Leufkens B, Cooper C: Use of HMG coA reductase inhibitors and Risk of Fractures. JAMA 2001, 285:1850-5
9. LaCroix AZ, Cauley JA, Jackson R, McGowan J, Pettinger M, Hsia J, Chen Z, Lewis C, Bauer DC, Daugherty S, McNeeley SG, Passaro M: Does HMG coA reductase inhibitor Use Reduce Risk of Fracture in Postmenopausal Women? Results from the Women's Health Initiative Observational Study. J Bone Miner Res 2000, 15(suppl 1):S155
10. Cauley JA, Jackson R, Pettinger M, LaCroix A, Bauer D, Chen Z, Hsia J, Daugherty S, Lewis C, McGowan J, McNeeley SG: HMG coA reductase inhibitor use and bone mineral density in older women: The Women's Health Initiative Observational Study. J Bone Miner Res 2000, 15(Suppl 1):S155
11. Chung Y-S, Lee M-D, Lee S-K, Kim H-M, Fitzpatrick LA: HMG-CoA Reductase Inhibitors Increase BMD in Type 2 Diabetes Mellitus Patients. J Clin Endocrinol Metab 2000, 85:1137-42
12. Stein EA, Farnier M, Liu M, Waldsteicher J, Mercuri: Do HMG coA reductase inhibitors Affect Bone Metabolism? Effects of Simvastatin and Atorvastatin on Biomarkers of Bone Turnover. JACC 2001, 37A:268A
13. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N, on behalf of the LIPID Study Group: Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Lancet 2001, 357:509-12
14. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S: Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000, 271:688-92
15. Lipid Research Clinics Program. Manual of Laboratory Operations, Revised. 1982
16. Chan MH, Mak TW, Chiu RW, Chow C, Chan IH, Lam CW: Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab 2001, 86:4556-9
17. Lennernas H, Fager G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997, 32:403-25
18. Lilja JJ, Kivisto KT, Neuvonen PJ: Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol 1999, 66:118-27
19. Christenson RH: Biochemical markers of bone metabolism: an overview. Clin Biochem 1997, 30:573-93
20. Machado AB, Hannon R, Eastell R: Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999, 14:602-8
21. Goldstein SR, Nachtigall LE: Quantitative Ultrasound of the Calcaneus: Comparison with Dual Energy X-ray Absorptiometry (DXA) of the Hip. Insights (Bedford, MA: Hologic, Inc) 1999, 10:16-17